Prognosis influence of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia with t(15;17)(q24;q21)

References

• Huynh TT, Sultan M, Vidovic D, et al. Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells. Sci Rep. 2019;9(1):9414. doi:10.1038/s41598-019-45982-7
   PubMedGoogle Scholar
• Rahimi N, Zhang Y, Mina A, et al. An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. Hum Pathol 2019;91:1–10. doi:10.1016/j.humpath.2019.05.008
   PubMed Web of Science ®Google Scholar
• Noguera NI, Catalano G, Banella C, et al. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers (Basel). 2019;11(10). doi:10.3390/cancers11111740
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: A paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–560. doi:10.1016/j.ccell.2017.10.002
   PubMed Web of Science ®Google Scholar
• De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–806. doi:10.1111/j.1365-2141.2000.02442.x
   PubMed Web of Science ®Google Scholar
• Ghaddar HM, Pierce S, Reed P, et al. Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype. Leukemia. 1995;9(5):779–782.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Sun Z, Gundacker H, et al. Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Med. Oncol. (Northwood, London, England). 2012;29(3):2095–2101. doi:10.1007/s12032-012-0251-7.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643. doi:10.1182/blood-2019-01-894980
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood. 1998;92(7):2322–2333.
   PubMed Web of Science ®Google Scholar
• Hernández JM, Martín G, Gutiérrez NC, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86(8):807–813.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang H, Chen L, et al. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Trials. 2018;19(1):476. doi:10.1186/s13063-018-2812-3.
   Google Scholar
• Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879. doi:10.1016/S1470-2045(18)30295-X
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–e366. doi:10.1016/S2352-3026(15)00115-5
   PubMed Web of Science ®Google Scholar
• O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Comprehensive Cancer Network. 2017;15(7):926–957. doi:10.6004/jnccn.2017.0116
   PubMed Web of Science ®Google Scholar
• Li J, Chen L, Zhu H, et al. Retinoic acid and arsenic trioxide with or without chemotherapy for acute promyelocytie leukemia with different risk stratifications: a interim analysis of China APL 2012 Study - ScienceDirect.
   Google Scholar
• Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;22(16):3432–3433. doi:10.1200/JCO.2004.99.116
   PubMed Web of Science ®Google Scholar
• Ono T, Takeshita A, Iwanaga M, et al. Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. Haematologica. 2011;96(1):174–176. doi:10.3324/haematol.2010.030205
   PubMed Web of Science ®Google Scholar
• Lou Y, Suo S, Tong H, et al. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leuk Res. 2013;37(11):1451–1456. doi:10.1016/j.leukres.2013.07.030
   PubMed Web of Science ®Google Scholar
• Wolman SR, Gundacker H, Appelbaum FR, et al. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002;100(1):29–35. doi:10.1182/blood.V100.1.29
   PubMed Web of Science ®Google Scholar
• Wang H, Cao F, Li J, et al. Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system. Blood. 2014;124(12):1998–2000. doi:10.1182/blood-2014-04-568121
   PubMed Web of Science ®Google Scholar
• Wang HY, Gong S, Li GH, et al. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood Cancer J. 2022;12(11):158. doi:10.1038/s41408-022-00753-y
   PubMed Web of Science ®Google Scholar